According to a report by AFP on May 22, according to a report released on the 21st, Dupilumab, an injectable drug used to treat eczema skin diseases, can be used to treat severe asthma, which means that it is known as a biological agent. The expensive drugs have a wider range of uses. Dupilumab (Dupixent) was approved by the U.S. Food and Drug Administration (FDA) in 2017. The drug manufacturer Regeneron Pharmaceuticals set the price at 37,000 U.S. dollars (about 236,000 U.S. dollars) per year. At present, Dupilumab has been tested in a randomized, controlled trial with more than 2,000 patients with moderate to severe asthma. The results showed that the injection of 200 to 300 milligrams of the drug every other week, compared to placebo, reduced the incidence of potentially fatal asthma by half. In 2018, the American Chest Association publicly released this study at a meeting in San Diego and published it in the New England Journal of Medicine. The study said the drug can also improve lung function in patients. At the same time, for those patients with more eosinophils (a particular type of white blood cell), the use of this drug reduced the asthma attack rate by two-thirds. The co-author of the study, Mario Castro, said: "This medicine can not only alleviate the serious illness of asthma, but also enhance the breathing ability of the patient." He is a professor and doctor of the University of Washington St. Louis School of Medicine. . He added: "This finding is very important, because as patients with this chronic disease go from bad to worse, their lung function is lost. So far, we have no drugs that change the condition of asthma." However, the drug also has side effects such as swelling and pain at the injection site. Five patients who received dupilumab injections and three patients who had received placebo died in the experiment. However, the investigators stated that these patients had a variety of serious diseases and that the injection of the drug was not the cause of their death. An additional editorial in the New England Journal of Medicine stated that the results of the study are likely to allow dupilumab to be approved for the treatment of severe asthma. This means that the other three biopharmaceuticals containing natural ingredients may also be used to treat asthma, including mepolizumab, reslizumab and benralizumab. The editors of the magazine, Jeffrey Drazen and Michael Harrington, wrote: "This new treatment is a significant improvement in the treatment of asthma." But they cautioned that they did not The real treatment for asthma is that it only alleviates the condition and therefore more research is needed. They said: "How do we choose treatment options? There is no more data, and these decisions are likely to be controlled by a variety of markets that produce these drugs." In response, they advocated: “The direct and practical experiments on these four new biopharmaceuticals for the treatment of asthma.†In addition, they said: “With the most efficient market, we will end the prescription treatment. Our patients are worth A better plan."(Hou Yahong Tian Ruizhe)
Plant extracts refer to substances extracted or processed from plants (all or a part of plants) using appropriate solvents or methods, and can be used in the pharmaceutical industry, food industry, daily chemical industry and other industries.
There is a conceptual overlap between plant extracts and herbal extracts. The raw materials of plant extracts in my country are mainly derived from Chinese herbal medicines, so domestic plant extracts can also be called Chinese medicine extracts to some extent.
Herbal Extract,Liquid Herbal Extracts,Herbal Extract Powder,Natural Herbal Extract XI AN RHINE BIOLOGICAL TECHNOLOGY CO.,LTD , https://www.rhinebiotech.com
